恒瑞医药：公司多款药品被纳入2025年国家医保目录

Core Viewpoint - Heng Rui Medicine (600276) announced on December 7 that several of its products have been included in the National Medical Insurance Directory as per the notice from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1: Inclusion in National Medical Insurance Directory - The following products have been newly included in the National Medical Insurance Directory: Injection of Rukang Qutuzumab, Apixaban Famitinib Capsules, Injection of Funaqi Qutuzumab, Sulfate of Amagatinib Tablets, Injection of Phosphororapitant Palonosetron, Injection of Ruikaxizumab, Acetate of Abiraterone Tablets (II), Lipid Injection of Irinotecan Hydrochloride (II), and Regaglitin Metformin Tablets (I)/(II), as well as Perfluorohexyl Octanoate Eye Drops [1] - The following products have successfully added new indications to the National Medical Insurance Directory: Injection of Karilizumab, Fluorazepam Capsules, and Injection of Fumaric Acid Tegafur [1] - The following products have successfully renewed their contracts to remain in the National Medical Insurance Directory: Maleate of Pyrotinib Tablets, Hecorapam Ethanolamine Tablets, Phosphate of Regaglitin Tablets, Injection of Tansuzumab, and Sulfate of Pevotizumab Injection [1] Group 2: Adjustments and Management - The indications for Methoxysulfonamide Apatinib Tablets and Lipid Injection of Bupivacaine have been newly added and adjusted to regular directory management [1]